Section Arrow
BMEA.NASDAQ
- Biomea Fusion
(Financial Status)
Quotes are at least 15-min delayed:2025/07/16 16:25 EDT
After Hours
Last
 1.91
0 (0.00%)
Bid
1.91
Ask
1.9
High 1.91 
Low 1.91 
Volume 26 
Regular Hours
Last
 1.91
+0.13 (+7.30%)
Day High 
1.93 
Prev. Close
1.78 
1-M High
3.08 
Volume 
697.37K 
Bid
1.91
Ask
1.9
Day Low
1.82 
Open
1.85 
1-M Low
1.58 
Market Cap 
101.50M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.82 
20-SMA 1.93 
50-SMA 1.9 
52-W High 13.07 
52-W Low 1.2905 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.54/-1.94
Enterprise Value
108.19M
Balance Sheet
Book Value Per Share
0.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APMAptorum Group Limited1.94+0.9702+100.04%2.77PE
After Hours 2.02 +0.08 +4.12%
TNFATNF Pharmaceuticals Inc.0.109+0.0028+2.64%-- 
After Hours 0.1034 -0.0056 -5.14%
NCNANuCana plc0.0502--0.000%-- 
After Hours 0.0503 +0.0001 +0.20%
BRNSBarinthus Biotherapeutics plc1.42+0.4+39.22%-- 
After Hours 1.33 -0.09 -6.34%
WINTWindtree Therapeutics Inc.0.9+0.0714+8.62%0.84PE
After Hours 0.8595 -0.0405 -4.50%
Quotes are at least 15-min delayed:2025/07/16 16:25 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.